Discover Biovet
Biovet started production in 1954 with chlortetracycline. The company boasts a long history, combined with traditions in creating products with applications in veterinary practice. Today, our product portfolio includes over 100 products that are sold all around the world.
Biovet AD produces its products at three production sites in Bulgaria in the towns of Peshtera, Botevgrad and Razgrad.The administrative management, institute for research and development, and creation of production facilities are in the town of Peshtera.
Since its founding, the company has significantly expanded its production capacity and at this stage has:
- specialized fermentation facilities
- workshops to produce chemical technical products
- a workshop for the isolation and purification of chemically pure active substances
- separate buildings for the production of granular premixes, and quality control laboratories - from inputs to finished products
- several ancillary facilities, including a modern treatment plant to reduce environmental pollution, and our own research and development institute
- a modern plant for the production of finished dosage forms
- a cogeneration plant for electricity and steam production
- a logistics center
Biovet AD is a leading European manufacturer of feed additives, premixes, active substances, finished products, enzymes and enzyme complexes, and vaccines for the treatment, prevention and improvement of animal health and productivity. The company develops intermediates and active substances for the pharmaceutical industry.
Biovet AD is a subsidiary of Huvepharma EOOD. Huvepharma EOOD is a private company based in Sofia. Huvepharma is a fast-growing pharmaceutical company focused on the development, production and marketing of veterinary and human medicinal products.
Huvepharma has offices in Belgium, France, Russia, Italy, Poland, Turkey, China, Thailand, Taiwan, India, Brazil, Mexico, Japan, Canada, South Africa and the United States.
Investment and innovation
The company has made significant investments in the renovation of production buildings and facilities by digitally automating the production process and building modern laboratories and warehouses. Currently, the production and administrative complex covers an area of approximately 150,000 m2. In 2019, Biovet invested in a new fermentation building which increased its production capacity to 10,000 m2.
The new plant has a total fermentation capacity of 3,500m3, including 21 process fermenters of 160m3 each and seven 20m3 culture and interim fermenters. This increased Huvepharma’s total production capacity by 30%.
Huvepharma has flexibility to ferment its entire current product portfolio in one place, with additional capacity remaining to introduce new products to our range in the future, giving you confidence in your supply of product.
Facilities at the new plant also include:
- workshops for processing, drying and product formulation
- state-of-the-art warehouse facilities
- a complete power station including high-voltage substation and the respective voltage-reduction facilities
- steam and compressed air production
- process and cooling water production and supply
- water and exhaust air treatment facilities
- underground and surface infrastructure
Innovations in the production process
Our commitment to constantly produce high quality products is demonstrated through significant investments in modern production facilities, high-tech laboratories, modern warehouses and leading quality assurance systems. Modern techniques and methods are introduced into the production process to ensure optimal performance.